Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene

Molecular Therapy

Volumn 16, Issue 7, 2008, Pages 1227-1234

  Wu, Shourong ^a,b   Nishiyama, Nobuhiro ^a,b   Kano, Mitsunobu R ^a,b   Morishita, Yasuyuki ^a   Miyazono, Kohei ^a   Itaka, Keiji ^a   Chung, Ung Il ^a,b   Kataoka, Kazunori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; EXPRESSION VECTOR; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; RNA INTERFERENCE; RNA VECTOR; UPREGULATION;

MUS;

EID: 45749145804     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.90     Document Type: Article

References (45)

1. Olsson, AK, Dimberg, A, Kreuger, J and Claesson-Welsh, L (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
2. Shibuya, M and Claesson-Welsh, L (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560.
3. Magnusson, P, Rolny, C, Jakobsson, L, Wikner, C, Wu, Y, Hicklin, DJ et al. (2004). Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development. J Cell Sci 117: 1513-1523.
4. Carmeliet, P, Ferreira, V, Breier, G, Pollefeyt, S, Kieckens, L, Gertsenstein, M et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
5. Detmar, M, Brown, LF, Schon, MP, Elicker, BM, Velasco, P, Richard, L et al. (1998). Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111: 1-6.
6. Bikfalvi, A, Klein, S, Pintucci, G and Rifkin, DB (1997). Biological roles of fibroblast growth factor-2. Endocr Rev 18: 26-45.
7. Lee, SH, Schloss, DJ, and Swain, JL (2000). Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J Biol Chem 275: 33679-33687.
8. Simons, M, Annex, BH, Laham, RJ, Kleiman, N, Henry, T, Dauerman, H et al. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105: 788-793.
9. Henry, TD, Annex, BH, McKendall, GR, Azrin, MA, Lopez, JJ, Giordano, FJ et al. (2003). The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107 1359-1365.
10. Lederman, RJ, Mendelsohn, FO, Anderson, RD, Saucedo, JF, Tenaglia, AN, Hermiller, JB et al. (2002). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359: 2053-2058.
11. Pepper, MS, Ferrara, N, Orci, L and Montesano, R (1992). Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189: 824-831.
12. Asahara, T, Bauters, C, Zheng, LP, Takeshita, S, Bunting, S, Ferrara, N et al. (1995). Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92: II365-II371.
13. Kano, MR, Morishita, Y, Iwata, C, Iwasaka, S, Watabe, T, Ouchi, Y et al. (2005). VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 118: 3759-3768.
14. Richardson, TP, Peters, MC, Ennett, AB and Mooney, DJ (2001). Polymeric system for dual growth factor delivery. Nat Biotechnol 19: 1029-1034.
15. Cao, R, Brakenhielm, E, Pawliuk, R, Wariaro, D, Post, MJ, Wahlberg, E et al. (2003). Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613.
16. Appelhoff, RJ, Tian, YM, Raval, RR, Turley, H, Harris, AL, Pugh, CW et al. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465.
17. Semenza, GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
18. Elson, DA, Thurston, G, Huang, LE, Ginzinger, DG, McDonald, DM, Johnson, RS et al. (2001). Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1a. Genes Dev 15: 2520-2532.
19. Kelly, BD, Hackett, SF, Hirota, K, Oshima, Y, Cai, Z, Berg-Dixon, S et al. (2003). Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93: 1074-1081.
20. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
21. Hannon, GJ and Rossi, JJ (2004). Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378.
22. Paddison, PJ, Silva, JM, Conklin, DS, Schlabach, M, Li, M, Aruleba, S et al. (2004). A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427-431.
23. Leung, RK and Whittaker, PA (2005). RNA interference: From gene silencing to gene-specific therapeutics. Pharmacol Ther 107: 222-239.
24. Behlke, MA (2006). Progress towards in vivo use of siRNAs. Mol Ther 13: 644-670.
25. Takeda, K and Fong, GH (2007). Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation. Hypertension 49: 178-184.
26. Busca, R, Berra, E, Gaggioli, C, Khaled, M, Bille, K, Marchetti, B et al. (2005). Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170: 49-59.
27. Berra, E, Benizri, E, Ginouves, A, Volmat, V, Roux, D and Pouyssegur, J (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22: 4082-4090.
28. Makinen, PI, Koponen, JK, Karkkainen, AM, Malm, TM, Pulkkinen, KH, Koistinaho, J et al. (2006). Stable RNA interference: Comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 8: 433-441.
29. Weinberg, RA and Penman, S (1968). Small molecular weight monodisperse nuclear RNA. J Mol Biol 38: 289-304.
30. Natarajan, R, Salloum, FN, Fisher, BJ, Kukreja, RC and Fowler, AA 3rd (2006). Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 98: 133-140.
31. Takeda, K, Cowan, A and Fong, GH (2007). Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116: 774-781.
32. Lee, RJ, Springer, ML, Blanco-Bose, WE, Shaw, R, Ursell, PC and Blau, HM (2000). VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102: 898-901.
33. Trentin, D, Hall, H, Wechsler, S and Hubbell, JA (2006). Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1α variant for local induction of angiogenesis. Proc Natl Acad Sci USA 103: 2506-2511.
34. Check, E (2005). A crucial test. Nat Med 11: 243-244.
35. Bitko, V, Musiyenko, A, Shulyayeva, O and Barik, S (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11 50-55.
36. Kim, DH and Rossi, JJ (2007). Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184.
37. Dykxhoom, DM and Lieberman, J (2006). Silencing viral infection. PLoS Med 3: E242.
38. Raoul, C, Barker, SO and Aebischer, P (2006). Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther 13: 487-495.
39. Miyata, K, Kakizawa, Y, Nishiyama, N, Harada, A, Yamasaki, Y, Koyama, H et al. (2004). Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression. J Am Chem Soc 126: 2355-2361.
40. Kanayama, N, Fukushima, 5, Nishiyama, N, Itaka, K, Jang, WD, Mlyata, K et al. (2006). A PEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells. ChemMedChem 1: 439-444.
41. Oishi, M, Nagasaki, Y, Itaka, K, Nishiyama, N and Kataoka, K (2005). Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc 127: 1624-1625.
42. Kakizawa, Y, Furukawa, S, Ishii, A and Kataoka, K (2006). Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J Control Release 111: 368-370.
43. Akagi, D, Oba, M, Koyama, H, Nishiyama, N, Fukushima, S, Miyata, T et al. (2007). Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther 14: 1029-1038.
44. Itaka, K, Ohba, S, Miyata, K, Kawaguchi, H, Nakamura, K, Takato, T et al. (2007). Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles. Mol Ther 15 1655-1662.
45. Wu, S, Murai, S, Kataoka, K and Miyagishi, M (2008). Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1. Biochem Biophys Res Commun 365: 75-81.